Alumis' Path Narrows Amid Promising Profile, Oppenheimer Says

MT Newswires Live11-17 03:14

Alumis (ALMS) is faced with a narrowing path forward amid a promising profile, Oppenheimer said in a report Sunday.

The note said envudeucitinib showed "rapid, robust, and durable" efficacy in psoriasis via the ONWARD clinical program.

"However, ALMS' need for a partner to compete commercially with JNJ's Icotyde and TAK's zasocitinib made the story challenging for investors, with no clear path forward on its own," it said. JNJ refers to Johnson & Johnson, and TAK to Takeda.

The note also said opportunity in systemic lupus erythematosus

narrows following positive competitor results.

Oppenheimer kept its outperform rating while lowering its price target to $28 from $37 after reducing penetration assumptions.

Price: 5.05, Change: -0.55, Percent Change: -9.82

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment